Patents by Inventor Heather Dawn Agnew

Heather Dawn Agnew has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS, IMAGING, AND THERAPEUTIC METHODS TARGETING FOLATE RECEPTOR 1 (FOLR1)
    Publication number: 20240053349
    Abstract: The present application provides stable heterobiligands made up of peptide-based FOLR1 ligands and folate (the ligand of FOLR1) and methods of use of the heterobiligands as detection, imaging, diagnostic, and therapeutic agents. The application further provides methods of manufacturing FOLR1 heterobiligands, capture agents, and imaging agents.
    Type: Application
    Filed: August 21, 2023
    Publication date: February 15, 2024
    Inventors: Heather Dawn Agnew, Anders Eliasen, Bert Tsunyin Lai
  • Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
    Patent number: 11884707
    Abstract: The present application provides stable peptide-based IDO1 capture agents and methods of use as detection, imaging, diagnostic and therapeutic agents. The application further provides methods of manufacturing IDO1 imaging agents.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: January 30, 2024
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Bert Tsunyin Lai, Heather Dawn Agnew
  • Compositions, delivery systems, and methods useful in tumor therapy
    Patent number: 11766414
    Abstract: Disclosed are compounds, compositions, systems, and methods useful for treating disease (such as cancer and tumors), or binding, detecting, and affecting compounds, compositions, cells, tissues, and organs, where the compounds, compositions, systems, and methods include or involve toxic compounds and where the toxic effect of the compounds, compositions, systems, and methods is reduced by providing a cleavage site to facilitate separation of the toxic component from other components of the compound, composition, or system. Preferably the system is a composition delivery system comprising or using a composition as disclosed herein. In some forms, the cleavage of the composition delivers a therapeutic agent and avoids organ damage by the composition.
    Type: Grant
    Filed: January 17, 2022
    Date of Patent: September 26, 2023
    Assignee: INDI MOLECULAR, INC.
    Inventors: Heather Dawn Agnew, Anders Eliasen, Bert Tsunyin Lai
  • Compositions, imaging, and therapeutic methods targeting folate receptor 1 (FOLR1)
    Patent number: 11733246
    Abstract: The present application provides stable heterobiligands made up of peptide-based FOLR1 ligands and folate (the ligand of FOLR1) and methods of use of the heterobiligands as detection, imaging, diagnostic, and therapeutic agents. The application further provides methods of manufacturing FOLR1 heterobiligands, capture agents, and imaging agents.
    Type: Grant
    Filed: January 12, 2022
    Date of Patent: August 22, 2023
    Assignee: INDI MOLECULAR, INC.
    Inventors: Heather Dawn Agnew, Anders Eliasen, Bert Tsunyin Lai
  • Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
    Patent number: 11723944
    Abstract: The present application provides stable peptide-based Botulinum neurotoxin (BoNT) serotype A capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing BoNT serotype A capture agents using iterative on-bead in situ click chemistry.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: August 15, 2023
    Assignees: INDI MOLECULAR, INC., CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Blake Farrow, James R. Heath, Heather Dawn Agnew
  • COMPOSITIONS, IMAGING, AND THERAPEUTIC METHODS TARGETING FOLATE RECEPTOR 1 (FOLR1)
    Publication number: 20220229066
    Abstract: The present application provides stable heterobiligands made up of peptide-based FOLR1 ligands and folate (the ligand of FOLR1) and methods of use of the heterobiligands as detection, imaging, diagnostic, and therapeutic agents. The application further provides methods of manufacturing FOLR1 heterobiligands, capture agents, and imaging agents.
    Type: Application
    Filed: January 12, 2022
    Publication date: July 21, 2022
    Inventors: Heather Dawn Agnew, Anders Eliasen, Bert Tsunyin Lai
  • COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY
    Publication number: 20220211648
    Abstract: Disclosed are compounds, compositions, systems, and methods useful for treating disease (such as cancer and tumors), or binding, detecting, and affecting compounds, compositions, cells, tissues, and organs, where the compounds, compositions, systems, and methods include or involve toxic compounds and where the toxic effect of the compounds, compositions, systems, and methods is reduced by providing a cleavage site to facilitate separation of the toxic component from other components of the compound, composition, or system. Preferably the system is a composition delivery system comprising or using a composition as disclosed herein. In some forms, the cleavage of the composition delivers a therapeutic agent and avoids organ damage by the composition.
    Type: Application
    Filed: January 17, 2022
    Publication date: July 7, 2022
    Inventors: Heather Dawn Agnew, Anders Eliasen, Bert Tsunyin Lai
  • BOTULINUM NEUROTOXIN-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
    Publication number: 20210369807
    Abstract: The present application provides stable peptide-based Botulinum neurotoxin (BoNT) serotype A capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing BoNT serotype A capture agents using iterative on-bead in situ click chemistry.
    Type: Application
    Filed: May 17, 2021
    Publication date: December 2, 2021
    Inventors: Blake Farrow, James R. Heath, Heather Dawn Agnew
  • Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
    Patent number: 11007245
    Abstract: The present application provides stable peptide-based Botulinum neurotoxin (BoNT) serotype A capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing BoNT serotype A capture agents using iterative on-bead in situ click chemistry.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: May 18, 2021
    Assignees: INDI MOLECULAR, INC., CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Blake Farrow, James R. Heath, Heather Dawn Agnew
  • COMPOSITIONS AND METHODS RELATING TO DETECTION, INHIBITION, AND IMAGING OF INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1)
    Publication number: 20200371101
    Abstract: The present application provides stable heterobiligands made up of peptide-based IDO1 ligands and small molecule inhibitors of IDO1 and methods of use of the heterobiligands as detection, imaging, diagnostic, and therapeutic agents. The application further provides methods of manufacturing IDO1 heterobiligands, capture agents, and imaging agents.
    Type: Application
    Filed: May 20, 2020
    Publication date: November 26, 2020
    Inventors: Heather Dawn Agnew, Bert Tsunyin Lai, Anders Eliasen
  • COMPOSITIONS FOR DETECTION, INHIBITION AND IMAGING OF INDOLEAMINE 2, 3-DIOXYGENASE 1 (IDO1) AND METHODS OF MAKING AND USING SAME
    Publication number: 20180355003
    Abstract: The present application provides stable peptide-based IDO1 capture agents and methods of use as detection, imaging, diagnostic and therapeutic agents. The application further provides methods of manufacturing IDO1 imaging agents.
    Type: Application
    Filed: September 29, 2017
    Publication date: December 13, 2018
    Inventors: Bert Tsunyin Lai, Heather Dawn Agnew
  • Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
    Patent number: 9913875
    Abstract: The present application provides stable peptide-based Botulinum neurotoxin (BoNT) serotype A capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing BoNT serotype A capture agents using iterative on-bead in situ click chemistry.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: March 13, 2018
    Assignees: California Institute of Technology, Indi Molecular, Inc.
    Inventors: Blake Farrow, James R. Heath, Heather Dawn Agnew
  • CD8-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
    Publication number: 20170319722
    Abstract: The present application provides stable peptide-based CD8 capture agents and methods of use as detection agents. The application further provides methods of manufacturing CD8 capture agents.
    Type: Application
    Filed: April 4, 2017
    Publication date: November 9, 2017
    Inventors: Heather Dawn Agnew, Bert Tsunyin Lai
  • BOTULINUM NEUROTOXIN-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
    Publication number: 20170218021
    Abstract: The present application provides stable peptide-based Botulinum neurotoxin (BoNT) serotype A capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing BoNT serotype A capture agents using iterative on-bead in situ click chemistry.
    Type: Application
    Filed: January 31, 2017
    Publication date: August 3, 2017
    Inventors: Blake Farrow, James R. Heath, Heather Dawn Agnew
  • VEGF-specific capture agents, compositions, and methods of using and making
    Patent number: 9221889
    Abstract: The present application provides biligand and triligand protein-catalyzed capture (PCC) agents that specifically bind VEGF, as well as the use of these capture agents as detection, diagnosis, and treatment agents.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: December 29, 2015
    Assignee: INDI MOLECULAR, INC.
    Inventors: Suresh Mark Pitram, Heather Dawn Agnew, Tsun Yin Lai, Rosemary Dyane Rohde, Paul Edward Kearney, Scott Law, Kenneth Charles Fang
  • PSA CAPTURE AGENTS, COMPOSITIONS, METHODS AND PREPARATION THEREOF
    Publication number: 20150093758
    Abstract: Disclosed herein are novel synthetic prostate specific antigen (PSA)-targeted capture agents that specifically bind PSA. In certain embodiments, these PSA capture agents are biligand or triligand capture agents containing two or three target-binding moieties, respectively.
    Type: Application
    Filed: July 28, 2014
    Publication date: April 2, 2015
    Inventors: James R. Heath, Heather Dawn Agnew, Suresh Mark Pitram
  • PSA capture agents, compositions, methods and preparation thereof
    Patent number: 8841083
    Abstract: Disclosed herein are novel synthetic prostate specific antigen (PSA)-targeted capture agents that specifically bind PSA. In certain embodiments, these PSA capture agents are biligand or triligand capture agents containing two or three target-binding moieties, respectively.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: September 23, 2014
    Assignees: California Institute of Technology, Indi Molecular, Inc.
    Inventors: James R. Heath, Heather Dawn Agnew, Suresh Mark Pitram
  • VEGF-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
    Publication number: 20140256630
    Abstract: The present application provides biligand and triligand protein-catalyzed capture (PCC) agents that specifically bind VEGF, as well as the use of these capture agents as detection, diagnosis, and treatment agents.
    Type: Application
    Filed: January 7, 2014
    Publication date: September 11, 2014
    Applicant: Indi Molecular, Inc.
    Inventors: Suresh Mark PITRAM, Heather Dawn AGNEW, Tsun Yin LAI, Rosemary Dyane ROHDE, Paul Edward Kearney, Scott LAW, Kenneth Charles FANG
  • VEGF-specific capture agents, compositions, and methods of using and making
    Patent number: 8710180
    Abstract: The present application provides biligand and triligand protein-catalyzed capture (PCC) agents that specifically bind VEGF, as well as the use of these capture agents as detection, diagnosis, and treatment agents.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: April 29, 2014
    Assignee: Indi Molecular, Inc.
    Inventors: Suresh Mark Pitram, Heather Dawn Agnew, Tsun Yin Lai, Rosemary Dyane Rohde, Paul Edward Kearney
  • VEGF-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
    Publication number: 20130156692
    Abstract: The present application provides biligand and triligand protein-catalyzed capture (PCC) agents that specifically bind VEGF, as well as the use of these capture agents as detection, diagnosis, and treatment agents.
    Type: Application
    Filed: August 31, 2012
    Publication date: June 20, 2013
    Applicant: Integrated Diagnostics, Inc.
    Inventors: Suresh Mark Pitram, Heather Dawn Agnew, Tsun Yin Lai, Rosemary Dyane Rohde, Paul Edward Kearney